bluebird bio Stock News

Maybe you are looking back at the 2020-2023 equity curve in your portfolio and are noticing an increasingly slowing upward trend. This is not your fault but rather the effects of the Federal Reserve (

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medic

Bluebird Bio's latest gene-editing therapy could have safety problems. The treatment's price also seems high compared to a notable competitor.

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 42nd Annual J

Investors may be tempted to go bottom-fishing after BlueBird Bio's share price drawdown. However, competition from two rivals and a large stock offering should make investors think twice.

Bluebird Bio has proven its innovative capabilities. However, the company likely won't turn a profit soon.

By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.

The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but tha

bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.

The plummeting share price is a potent symbol of the structural problems still facing small and midsize biotechs.

Biotech company bluebird bio Inc (NASDAQ:BLUE) has priced its underwritten public offering, making 83,333,333 shares of common stock available at $1.50 per share. The offering, expected to yield $125

bluebird bio Inc (NASDAQ:BLUE) shares took off on Thursday after the biotechnology company provided positive patient start guidance for the new year and revealed a commercial agreement with a U.S. pay

Wall Street loves a good comeback story. It's why analysts often put elevated price targets on severely beaten-down stocks.